Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(02): 119-124
DOI: 10.1055/s-0041-1731949
Original Article

Polymorphism in Apolipoprotein C3 (APOC3) and Fatty Acid-Binding Proteins (FABP2) Genes in Nondiabetic Dyslipidemic Patients: A Tertiary Care Hospital-Based Pilot Study

Rashmi Chowdhary
1   Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India
,
Neha Masarkar
1   Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India
,
Sagar Khadanga
2   Department of Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India
› Author Affiliations Funding This study is funded by Institutional Intramural Research Funding (LOP/2017/IM0147).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Context Dyslipidemia is a multifactorial disease in which lipoproteins play an important role as one of the early markers for coronary heart disease (CHD). Mixed dyslipidemia is common in people with diabetes mellitus, but nondiabetic dyslipidemics (NDD) remain unidentified for the risk of developing dyslipidemia and eventually CHD.

Objectives This pilot study attempts to analyze the genetic basis of lipid metabolism alterations, emphasizing the association between fatty acid-binding protein-2 (FABP2-Ala54Thr) and apolipoprotein-C3 (APOC3-rs5128) genetic polymorphism, as a risk for developing dyslipidemia and CHD in NDD.

Methods and Design Total 90 subjects—30 DD, 30 NDD, and 30 apparently healthy subjects representing Central India—were included. Biochemical analysis and DNA genotyping were done by polymerase chain reaction restriction fragment length polymorphism.

Statistical Analysis The biochemical parameters were reported as means ± standard deviation. One-way analysis of variance test was used to compare biochemical parameters of three groups. Chi-squared test was done to compare genotype distributions. The strength of association was assessed by odds ratios (ORs) with 95% confidence intervals (CIs). All statistical analysis was done using SPSS-PC software and Graph Pad.

Results In NDD, maximum polymorphism was observed followed by DD and least polymorphism was observed in controls. There was a significant association of APOC3 G allele with occurrence of hypertriglyceridemia (p < 0.05); however, no such association was found for FABP2 A allele (p > 0.05). Logistic regression analysis revealed APOC3 polymorphism to be significantly associated with dyslipidemia (OR = 2.6667, 95% CI = 1.0510–6.7663, p = 0.0341); no such association was found for FABP2 polymorphism (OR = 0.4643, 95% CI = 0.1641–1.3136, p = 0.1347). The triglyceride and cholesterol values in individuals with homozygous genotype indicate that genetic study is comparable to the biochemical findings in carriers of polymorphic allele than noncarriers, especially in NDD patients.

Conclusions Pilot study indicates that the presence of APOC3 gene polymorphism is associated with pro-atherogenic dyslipidemia in nondiabetic patients and may raise risk of CHD. This information could be used for preventive strategies in NDD group that may otherwise go unnoticed.

Keywords

APOC3 - dyslipidemia - FABP2 - nondiabetic - polymorphism


Publication History

Article published online:
14 July 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Stein R, Ferrari F, Scolari F. Genetics, dyslipidemia, and cardiovascular disease: new insights. Curr Cardiol Rep 2019; 21 (08) 68
    CrossrefPubMedGoogle Scholar
  • 2 Ni WQ, Liu XL, Zhuo ZP. et al. Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen. Lipids Health Dis 2015; 14: 71
    CrossrefPubMedGoogle Scholar
  • 3 Guptha S, Gupta R, Deedwania P. et al. Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study. Indian Heart J 2014; 66 (03) 280-288
    CrossrefPubMedGoogle Scholar
  • 4 Geldsetzer P, Manne-Goehler J, Theilmann M. et al. Geographic and sociodemographic variation of cardiovascular disease risk in India: a cross-sectional study of 797,540 adults. PLoS Med 2018; 15 (06) e1002581
    CrossrefPubMedGoogle Scholar
  • 5 Burgess S, Harshfield E. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future. Curr Opin Endocrinol Diabetes Obes 2016; 23 (02) 124-130
    CrossrefPubMedGoogle Scholar
  • 6 Mihăilă RG. Pragmatic analysis of dyslipidemia involvement in coronary artery disease: a narrative review. Curr Cardiol Rev 2019
    Google Scholar
  • 7 Larifla L, Rambhojan C, Joannes MO. et al. Gene polymorphisms of FABP2, ADIPOQ and ANP and risk of hypertriglyceridemia and metabolic syndrome in Afro-Caribbeans. PLoS One 2016; 11 (09) e0163421
    CrossrefPubMedGoogle Scholar
  • 8 Cui F, Li K, Li Y, Zhang X, An C. Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population. Lipids Health Dis 2014; 13: 170
    CrossrefPubMedGoogle Scholar
  • 9 Chhabra S, Narang R, Krishnan LR. et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet 2002; 3: 9
    CrossrefPubMedGoogle Scholar
  • 10 Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci 2015; 36 (10) 675-687
    CrossrefPubMedGoogle Scholar
  • 11 Song Y, Zhu L, Richa M, Li P, Yang Y, Li S. Associations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis. Lipids Health Dis 2015; 14: 32
    CrossrefPubMedGoogle Scholar
  • 12 Smith CE, Tucker KL, Scott TM. et al. Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One 2009; 4 (05) e5465
    CrossrefPubMedGoogle Scholar
  • 13 Ríos-González BE, Luévano-Ortega KE, Saldaña-Cruz AM, González-García JR, Magaña-Torres MT. Polymorphisms of seven genes involved in lipid metabolism in an unselected Mexican population. J Genet 2011; 90 (03) e114-e119
    PubMedGoogle Scholar
  • 14 Auinger A, Helwig U, Rubin D. et al. Human intestinal fatty acid binding protein 2 expression is associated with fat intake and polymorphisms. J Nutr 2010; 140 (08) 1411-1417
    CrossrefPubMedGoogle Scholar
  • 15 Khattab SA, Abo-Elmatty DM, Ghattas MH, Mesbah NM, Mehanna ET. Intestinal fatty acid binding protein Ala54Thr polymorphism is associated with peripheral atherosclerosis combined with type 2 diabetes mellitus. J Diabetes 2017; 9 (09) 821-826
    CrossrefPubMedGoogle Scholar
  • 16 Salto LM, Bu L, Beeson WL, Firek A, Cordero-MacIntyre Z, De Leon M. The Ala54Thr polymorphism of the fatty acid binding protein 2 gene modulates HDL cholesterol in Mexican-Americans with type 2 diabetes. Int J Environ Res Public Health 2015; 13 (01) h13010052
    CrossrefPubMedGoogle Scholar
  • 17 Lakbakbi El Yaagoubi F, Charoute H, Morjane I. et al. Association analysis of genetic variants with metabolic syndrome components in the Moroccan population. Curr Res Transl Med 2017; 65 (03) 121-125
    CrossrefPubMedGoogle Scholar
  • 18 Li S, Guo YL, Zhao X. et al. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Sci Rep 2017; 7 (01) 360
    CrossrefPubMedGoogle Scholar
  • 19 Natarajan P, Kohli P, Baber U. et al. Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis: the multi-ethnic BioImage Study. J Am Coll Cardiol 2015; 66 (18) 2053-2055
    CrossrefPubMedGoogle Scholar
  • 20 García-Giustiniani D, Stein R. Genetics of dyslipidemia. Arq Bras Cardiol 2016; 106 (05) 434-438
    PubMedGoogle Scholar
  • 21 Zhang H, Temel RE, Martel C. Cholesterol and lipoprotein metabolism: Early Career Committee contribution. Arterioscler Thromb Vasc Biol 2014; 34 (09) 1791-1794
    CrossrefPubMedGoogle Scholar
  • 22 Chrispin J, Martin SS, Hasan RK. et al. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease. Clin Cardiol 2013; 36 (09) 516-523
    CrossrefPubMedGoogle Scholar